Eucalyptol reduces airway hyperresponsiveness in rats following cigarette smoke-exposed
ConclusionEUC reduces the hyperresponsiveness and the airway inflammatory profile, recovering the lung function. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - January 9, 2020 Category: Respiratory Medicine Source Type: research

Asthma phenotypes and T-bet protein expression in cells treated with Fluticasone Furoate/Vilanterol
In this study T-bet expression was attested in CD4 T cells treated with Fluticasone Furoate (FF), Vilanterol (V) and FF/V combination in severe asthmatic patients compared to patients with moderate asthma and healthy controls using Immunocytochemistry (ICC). First, CD4 T cells were isolated from PBMCs of 12 patients and controls using CD4 T cell isolation kit. Subsequently, isolated CD4 T cells were cultured with FF, V and FF/V for 1 h. To accomplish ICC, cells were incubated with anti-T-bet antibody, and then stained with HRP-bound secondary antibody. T-bet expression was evaluated using light microscopy. Statistical an...
Source: Pulmonary Pharmacology and Therapeutics - January 7, 2020 Category: Respiratory Medicine Source Type: research

Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis
Publication date: February 2020Source: Pulmonary Pharmacology & Therapeutics, Volume 60Author(s): Theodoros Karampitsakos, Ourania Papaioannou, Maria Kaponi, Andreana Kozanidou, Georgios Hillas, Elisavet Stavropoulou, Demosthenes Bouros, Katerina DimakouAbstractPlasma drug concentrations, spectrum of antibacterial activity and minimum inhibitory concentration (MIC) had been widely considered as markers of the efficacy of antibiotics. Nonetheless, in several cases, antibiotics characterized by all these features were ineffective for the treatment of respiratory tract infections. A typical paradigm represented the case o...
Source: Pulmonary Pharmacology and Therapeutics - January 7, 2020 Category: Respiratory Medicine Source Type: research

Low penetrance of antibiotics in the epithelial lining fluid. Experience from the use of inhaled antibiotics in patients with non CF-bronchiectasis
Publication date: Available online 28 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Ourania Papaioannou, Maria Kaponi, Andreana Kozanidou, Georgios Hillas, Elisavet Stavropoulou, Demosthenes Bouros, Katerina DimakouAbstractPlasma drug concentrations, spectrum of antibacterial activity and minimum inhibitory concentration (MIC) had been widely considered as markers of the efficacy of antibiotics. Nonetheless, in several cases, antibiotics characterized by all these features were ineffective for the treatment of respiratory tract infections. A typical paradigm represented t...
Source: Pulmonary Pharmacology and Therapeutics - December 30, 2019 Category: Respiratory Medicine Source Type: research

The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo
In this study, we investigated the individual antimicrobial activity of HT61 alongside its capability to increase the efficacy of tobramycin against both a tobramycin sensitive laboratory reference strain (PAO1) and tobramycin resistant clinical isolates (RP73, NN2) of the gram-negative bacteria Pseudomonas aeruginosa (P. aeruginosa). Using broth microdilution methods, the MICs of HT61 against all strains were assessed, as well as the effect of HT61 in combination with tobramycin using both the chequerboard method and bacterial time-kill assays. A murine model of pulmonary infection was also used to evaluate the combinatio...
Source: Pulmonary Pharmacology and Therapeutics - December 28, 2019 Category: Respiratory Medicine Source Type: research

A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study
Publication date: Available online 26 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Maria Gabriella Matera, Marc F. Goldstein, William R. Fairweather, William W. Howard, Mario Cazzola, Paola RoglianiAbstractDoxofylline, an oral methylxanthine with bronchodilator and anti-inflammatory activities, offers a promising alternative to theophylline due to its superior efficacy/safety profile. No long-term studies on the efficacy and safety on doxofylline are currently available in asthma. The aim of the Long-term clinical trial on the Efficacy and Safety profile of Doxofylline in Asthm...
Source: Pulmonary Pharmacology and Therapeutics - December 27, 2019 Category: Respiratory Medicine Source Type: research

Prospective evaluation for inhalation devices in greek patients with COPD and asthma: The PAIR study
Publication date: Available online 24 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Georgios Hillas, Eleftherios Zervas, Petros Bakakos, Grigorios Stratakos, Katerina Dimakou, Effrosyni Manali, Demosthenes Bouros, Spyridon Papiris, Argyrios Tzouvelekis, Adamidis Vasilios, Adamou Helen, Agelidis Xenophon, Albantakis Konstantinos, Anaplioti Aikaterini, Babalis Christos, Balasoulis George, Christou Konstantinos, Filippidou Elisavet Christina, Fothiantakis EmmanuelAbstractIntroductionChronic obstructive pulmonary disease (COPD) and asthma remain a major health burden. Adheren...
Source: Pulmonary Pharmacology and Therapeutics - December 25, 2019 Category: Respiratory Medicine Source Type: research

Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
ConclusionsIPF is a risk factor for lung cancer development. In line with current literature, squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 24, 2019 Category: Respiratory Medicine Source Type: research

Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2–5
In conclusion, Tiotropium Respimat add-on therapy improves lung function, and may improve asthma control, in adults across disease severities.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 24, 2019 Category: Respiratory Medicine Source Type: research

Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients
Publication date: Available online 20 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Giovanna E. Carpagnano, Giulia Scioscia, Donato Lacedonia, Silvia Romana Stornelli, Carla Maria Irene Quarato, Piera Soccio, Onofrio Resta, Maria Pia Foschino BarbaroAbstractBackgroundInflammation in small airways is particularly clinically active in severe asthma but they still continue to be ignored as considered silent. Recently, the Atlantis study reports small airways involvement in 91% of the asthma population. Therefore in the era of phenotype driven therapy, the aim of this study was to verify if high-stre...
Source: Pulmonary Pharmacology and Therapeutics - December 20, 2019 Category: Respiratory Medicine Source Type: research

Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients
Publication date: Available online 17 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): André Terras Alexandre, Natália Martins, Sara Raimundo, Natália Melo, Patrícia Caetano Mota, Hélder Novais e Bastos, José Miguel Pereira, Rui Cunha, Susana Guimarães, Conceição Souto Moura, António MoraisAbstractIntroductionSystemic corticosteroids are widely used in chronic hypersensitivity pneumonitis (CHP); however, there is not much evidence to support their use, besides being associated with significant side effects. Azathioprine (AZA) use ...
Source: Pulmonary Pharmacology and Therapeutics - December 18, 2019 Category: Respiratory Medicine Source Type: research

Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study
Publication date: Available online 16 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Francesco Menzella, Carla Galeone, Patrizia Ruggiero, Diego Bagnasco, Chiara Catellani, Nicola FacciolongoAbstractThe increasing knowledge on immuno-inflammatory pathways allowed the development of new therapeutic options in the field of severe refractory asthma (SRA). It is therefore very important to accurately identify phenotypes and endotypes of patients potentially eligible for innovative treatments. The aim of this study was to describe a cohort of patients affected by SRA referring to the Pneumology Unit of...
Source: Pulmonary Pharmacology and Therapeutics - December 17, 2019 Category: Respiratory Medicine Source Type: research

FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods
ConclusionMaximum reduction in FEV1 had the lowest variability. There was little difference between repetitions of the same methodology, as indicated by overlapping confidence intervals. There was a trend towards faster recovery following bolus challenge than with the incremental challenge. The results of this trial could be of value when designing future clinical trials using the methacholine challenge methodology. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 15, 2019 Category: Respiratory Medicine Source Type: research

The role of increased red cell distribution width as a negative prognostic marker in patients with COPD
Publication date: Available online 13 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Theodoros Karampitsakos, Katerina Dimakou, Ourania Papaioannou, Serafeim Chrysikos, Maria Kaponi, Demosthenes Bouros, Argyrios Tzouvelekis, Georgios HillasAbstractIntroductionChronic obstructive pulmonary disease (COPD) remains a major burden with no clinically applicable biomarkers.AimTo investigate the association of Red cell Distribution Width (RDW) values on admission with previous hospitalizations, need of non-invasive mechanical ventilation(NIMV) and long term oxygen therapy (LTOT)in patients with COPD.Metho...
Source: Pulmonary Pharmacology and Therapeutics - December 15, 2019 Category: Respiratory Medicine Source Type: research

The leukotriene receptor antagonist Montelukast can induce adverse skin reactions in asthmatic patients
Publication date: Available online 11 December 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Eleonora Di Salvo, Vincenzo Patella, Marco Casciaro, Sebastiano GangemiAbstractMontelukast the leukotriene receptor antagonist is an anti-inflammatory drug that causes bronchodilation and for this reason it is used to improve inflammatory states in asthma and allergic rhinitis. Montelukast is generally considered a safe drug with the occurrence of a few adverse drug reactions (ADRs) and anti-leucotrienes are usually well-tolerated by adults and young patients. Starting from these premises the purpose of this revie...
Source: Pulmonary Pharmacology and Therapeutics - December 11, 2019 Category: Respiratory Medicine Source Type: research

Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD
ConclusionsSteady-state PK parameters of budesonide, glycopyrronium, and formoterol were similar after 7 days’ dosing in the phase I PK study and after 24 weeks in the KRONOS PK sub-study. Systemic exposure to budesonide, glycopyrronium, and formoterol was generally comparable across treatments in the KRONOS PK sub-study, suggesting no meaningful drug–drug or within-formulation PK interactions. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 10, 2019 Category: Respiratory Medicine Source Type: research

Zileuton use and phenotypic features in asthma
ConclusionIn this retrospective study, zileuton response varies across asthmatics, with poorer response rates being associated with those with severe asthma and possibly obesity. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - December 10, 2019 Category: Respiratory Medicine Source Type: research

Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India
Publication date: Available online 30 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Aloke Ghoshal, Pradyut Waghray, George Dsouza, Mahip Saluja, Mayank Agarwal, Ashish Goyal, Sneha Limaye, Akash Balki, Sudhir Bhatnagar, Manish Jain, Sharad Tikkiwal, Abhijit Vaidya, Meena Lopez, Rashmi Hegde, Jaideep GogtayAbstractThe combination of inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) is widely used for the management of asthma. This prospective, open-label, non-comparative, observational, 24-week multicentre study is the first real-world study from India to compare the efficacy an...
Source: Pulmonary Pharmacology and Therapeutics - December 1, 2019 Category: Respiratory Medicine Source Type: research

C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD
ConclusionWe did not find a reduced risk of moderate and/or severe COPD exacerbations among COPD patients with varying CRP levels currently exposed to ICS. However, low-grade systemic inflammation was associated with all-cause mortality among COPD patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 29, 2019 Category: Respiratory Medicine Source Type: research

Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series
ConclusionsEndobronchial administration of ε-aminocaproic acid during bronchoscopy may be a safe and efficacious option in the treatment and prevention of pulmonary bleeding. Further studies are necessary to better define ε-aminocaproic acid's safety profile, optimal routes of administration, and comparative effectiveness to tranexamic acid. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 26, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: December 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 59Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - November 16, 2019 Category: Respiratory Medicine Source Type: research

Antistatic treatment and salbutamol dosing have variable effect on drug delivery of valved holding chambers
ConclusionVHCs marketed as antistatic are significantly affected by antistatic treatment. To ensure optimal drug delivery, salbutamol should be actuated to VHCs one puff at a time. Each VHC brand has its unique characteristic that affects drug delivery in a way that cannot be generalised to another VHC. There is a need for universal standardisation of VHCs.Key notesValved holding chambers (VHCs) that are marketed as antistatic are significantly affected by antistatic treatment. Multiple actuations before inhalation tend to decrease the drug delivery efficacy of VHCs. Each VHC brand has its unique characteristic that affect...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Interfering with airway nerves in cough associated with asthma
Publication date: Available online 1 November 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Akio Niimi, Kensuke Fukumitsu, Norihisa Takeda, Yoshihiro KanemitsuAbstractCough is a troublesome and often refractory symptom of asthma, which is associated with poor control of disease. The pathogenesis of asthmatic cough has mainly been attributed to bronchoconstriction, but recent evidence indicate that cough reflex hypersensitivity or neuronal dysfunction is a feature of asthma, even in those with mild stable disease. This is likely resistant to the mainstay treatment ICS/LABA which inhibits classic asthmatic ...
Source: Pulmonary Pharmacology and Therapeutics - November 1, 2019 Category: Respiratory Medicine Source Type: research

Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis
ConclusionsThe results of this meta-analysis show that LABA/LAMA combinations are consistently more effective than ICS/LABA FDCs for most of the evaluated outcomes. However, differences have also been observed between FDCs belonging to the same class. Across the investigated LABA/LAMA FDCs, glycopyrronium/indacaterol revealed a consistent and robust efficacy profile. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 20, 2019 Category: Respiratory Medicine Source Type: research

Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques
Publication date: Available online 15 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Martina Oriano, Leonardo Terranova, Giovanni Sotgiu, Laura Saderi, Angela Bellofiore, Mariangela Retucci, Cinzia Marotta, Andrea Gramegna, Daniela Miglietta, Chiara Carnini, Paola Marchisio, James D. Chalmers, Stefano Aliberti, Francesco BlasiAbstractNeutrophil elastase (NE) is a crucial marker of neutrophilic inflammation. We aimed to compare different techniques to detect active NE in sputum samples of 50 Bronchiectasis (BE) and 50 Cystic Fibrosis (CF) patients. Three methods including a ProteaseTag® Active N...
Source: Pulmonary Pharmacology and Therapeutics - October 16, 2019 Category: Respiratory Medicine Source Type: research

Emerging targets for cough therapies; NK1 receptor antagonists
Publication date: Available online 14 October 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Huda Badri, Jaclyn A. SmithAbstractCough is mediated by vagal afferent fibres innervating the larynx and proximal airways. Pre-clinical studies suggest that vagal C fibres produce Substance P, one of the tachykinin family of neuropeptides, which has been shown to enhance cough via the neurokinin-1 (NK-1) receptor and studies in animal models have also shown that NK-1 antagonists are effective at blocking induced cough. In the past, tachykinin receptor antagonists have yielded disappointing results in treating asthm...
Source: Pulmonary Pharmacology and Therapeutics - October 15, 2019 Category: Respiratory Medicine Source Type: research

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands
ConclusionXC8 was safe and well tolerated. A phase 2 study is being performed to further evaluate the potential role of XC8 in asthma treatment.Trial registrationClinicalTrials.gov, NCT02882217. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - October 7, 2019 Category: Respiratory Medicine Source Type: research

Progress in cough hypersensitivity at the Tenth London International Cough Symposium 2018 (10th LICS 2018)
Publication date: Available online 26 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Kian Fan Chung, Lorcan McGarvey, Stuart B. Mazzone (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes
ConclusionsIn conclusion, our data support the growing hypothesis that doxofylline does not have a superimposable mechanism of action compared to theophylline, and this may both explain some differences in the risk/benefit ratio and may direct studies to tailor therapy for patients. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 27, 2019 Category: Respiratory Medicine Source Type: research

Isolated airways in equine respiratory pharmacology: They never lie
Publication date: Available online 22 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Luigino Calzetta, Elena Pistocchini, Beatrice Ludovica Ritondo, Paola Roncada, Giuseppe Cito, Domenico Britti, Maria Gabriella MateraAbstractPre-clinical studies on human isolated bronchi have relevant translational value in human in vivo, conversely no investigation has been performed to assess whether data resulting from equine isolated airways can have any translational application in asthmatic horses. Thus, a meta-regression analysis via random-effect method was carried out to correlate the pharmacological ch...
Source: Pulmonary Pharmacology and Therapeutics - September 24, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: October 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 58Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 22, 2019 Category: Respiratory Medicine Source Type: research

Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice
ConclusionTaken together, these results suggested that inhibition of the PD-1/PD-L1 signaling pathway enhanced the innate immune response of alveolar macrophages to Mycobacterium TB in mice. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 18, 2019 Category: Respiratory Medicine Source Type: research

Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations
Publication date: Available online 11 September 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Paola Rogliani, Maria Gabriella Matera, Beatrice Ludovica Ritondo, Ilaria De Guido, Ermanno Puxeddu, Mario Cazzola, Luigino CalzettaAbstractDespite several long-acting β2-adrenoceptors agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are currently approved in chronic obstructive pulmonary disease (COPD), there are limited findings concerning the direct comparison across the different LABA/LAMA FDCs. The aim of this study was to compare the efficacy/safety profile of appr...
Source: Pulmonary Pharmacology and Therapeutics - September 11, 2019 Category: Respiratory Medicine Source Type: research

Mycophenolate mofetil as an alternative treatment in sarcoidosis
ConclusionMMF as an alternative drug in systemic sarcoidosis, proved safe and effective, permitting the reduction of the dose of oral CS and leading to clinical, functional and radiological improvement. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 10, 2019 Category: Respiratory Medicine Source Type: research

Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis
ConclusionsWeight loss is common among IPF patients on antifibrotic therapy. Nintedanib therapy and more advanced disease were identified as predictors of weight loss in this population. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 10, 2019 Category: Respiratory Medicine Source Type: research

Quantifying test-retest variability of natural and suppressed citric acid cough thresholds and urge to cough ratings
ConclusionsNatural and suppressed cough thresholds and UTC ratings are subject to test-retest variability. These data are important for the use of citric acid CRT as an outcome measure in longitudinal cough research, as they facilitate interpretation of whether changes in citric acid cough thresholds across days reflect true changes in cough sensitivity, rather than an artefact of repeating the test. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - September 5, 2019 Category: Respiratory Medicine Source Type: research

Challenges and perspectives in porcine model of acute lung injury using oleic acid
The objective of this study was to evaluate a protocol of administration of OA in lung injury model, challenges in its development and its effects on respiratory mechanics, hemodynamic changes, histology, gas exchange and mortality. We then submitted ten Large White pigs to acute lung injury through intravenous infusion of acid oleic in the pulmonary artery. The mortality of the model was 50%, due to an intense hemodynamic instability during OA administration, even with early use of vasoactive drugs. Three animals required additional doses of OA to achieve criteria for acute lung injury. Histology showed findings consisten...
Source: Pulmonary Pharmacology and Therapeutics - September 4, 2019 Category: Respiratory Medicine Source Type: research

One year of mepolizumab. Efficacy and safety in real-life in Italy
Publication date: Available online 29 August 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Diego Bagnasco, Marco Caminati, Francesco Menzella, Manlio Milanese, Giovanni Rolla, Carlo Lombardi, Caterina Bucca, Enrico Heffler, Giovanni Paoletti, Elisa Testino, Andrea Manfredi, Cristiano Caruso, Giuseppe Guida, Gianenrico Senna, Marco Bonavia, Anna Maria Riccio, Giorgio Walter Canonica, Giovanni PassalacquaAbstractBackgroundSevere asthma is a disease with a heavy socio-economic burden and a relevant impact on the life of patients. Mepolizumab (MEP) was recently introduced in practice. The previous data were f...
Source: Pulmonary Pharmacology and Therapeutics - August 30, 2019 Category: Respiratory Medicine Source Type: research

ATP cough challenge
Publication date: October 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 58Author(s): Alyn Morice (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - August 20, 2019 Category: Respiratory Medicine Source Type: research

Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1)
Publication date: Available online 18 August 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Michael R. Loebinger, Eva Polverino, Francesco Blasi, Stuart J. Elborn, James D. Chalmers, Harm AWM. Tiddens, Herman Goossens, Michael Tunney, Wenchun Zhou, Gerhild Angyalosi, Adam T. Hill, Charles S. Haworth, iBEST-1 Trial TeamAbstractIn patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease progression, frequent pulmonary exacerbations and lung function decline. However, at present, no inhaled antibiotics have been approved for the treatment of these patients. Tobramycin i...
Source: Pulmonary Pharmacology and Therapeutics - August 18, 2019 Category: Respiratory Medicine Source Type: research

Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation
Publication date: Available online 1 August 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Di Wang, Xiao-qing Chai, Costan G. Magnnusen, Graeme R. Zosky, Shu-hua Shu, Xin Wei, Shan-shan HuAbstractWhile effective treatments for acute respiratory distress syndrome (ARDS) are lacking, mechanical lung ventilation can sustain adequate gas exchange in critically ill patients with respiratory failure due to ARDS. However, as a result of the phenomenon of ventilator-induced lung injury (VILI), there is an increasing need to seek beneficial pharmacological therapies for ARDS. Recent studies have suggested the renin...
Source: Pulmonary Pharmacology and Therapeutics - August 1, 2019 Category: Respiratory Medicine Source Type: research

Evaluation of patients’ real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition
ConclusionsUsing the R under the fluctuating summer and winter environments of our patients would not affect its overall tiotropium bromide emission performance. The significant increase in the respirable mass of the RS and RW might be offset by the increase in particles
Source: Pulmonary Pharmacology and Therapeutics - July 26, 2019 Category: Respiratory Medicine Source Type: research

Airway delivery of conditioned media from mesenchymal stem cells (MSC-CM) for COPD
Publication date: Available online 24 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Avinash Kharat, Vikrant R. Patil, Supriya Kheur, Ramesh Bhonde (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment
Publication date: Available online 23 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Maria Gabriella Matera, Barbara Rinaldi, Luigino Calzetta, Paola Rogliani, Mario CazzolaAbstractThe differences in the pharmacokinetic (PK) characteristics of inhaled corticosteroids (ICSs) critically influence the profile of each of them, but also the significant differences in glucocorticoid receptor selectivity, potency, and physicochemical properties are critical in defining the pharmacodynamic (PD) profile of an ICS. The PK and PD properties of ICSs used in asthma and the importance of their interrelationship hav...
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study
ConclusionThese data suggest that the improvement in lung function and quality of life in COPD patients may probably be attributed to the antioxidant, anti-inflammatory and anti-MMP activity of doxycycline. The potential therapeutic role of long-term doxycycline, in addition to its traditional antibiotic effect, definitely warrants further attention.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 25, 2019 Category: Respiratory Medicine Source Type: research

Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose
Publication date: Available online 22 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Corrado Pelaia, Maria Teresa Busceti, Alessandro Vatrella, Giuseppe Francesco Rago, Claudia Crimi, Rosa Terracciano, Girolamo PelaiaAbstractBenralizumab is a humanized monoclonal antibody which binds to the α subunit of the interleukin-5 (IL-5) receptor and to the FcγRIIIa receptor expressed by natural killer cells, thus suppressing the pro-eosinophil actions of IL-5 and triggering eosinophil apoptosis via the very effective mechanism of antibody-dependent cell-mediated cytotoxicity (ADCC). Because of its ...
Source: Pulmonary Pharmacology and Therapeutics - July 23, 2019 Category: Respiratory Medicine Source Type: research

A systematic review of methods of citric acid cough reflex testing
ConclusionsConsiderable methodological variability exists for citric acid CRT in published literature. The findings suggest that caution is warranted in comparing citric acid cough thresholds across studies. Full replication of previously published methods of citric acid CRT is limited due to crucial elements of the citric acid CRT protocol being omitted from published manuscripts. These findings have implications on the use of citric acid CRT in clinical and pharmaceutical studies to evaluate the effects of antitussive medications and cough therapies. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 19, 2019 Category: Respiratory Medicine Source Type: research

Editorial Board
Publication date: August 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 57Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 17, 2019 Category: Respiratory Medicine Source Type: research

Publisher’s Note
Publication date: Available online 12 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 13, 2019 Category: Respiratory Medicine Source Type: research

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis
ConclusionsSPX-101 was well-tolerated across a range of doses and had little/no systemic exposure in healthy adults and adults with CF, thus supporting further study in patients with CF.Clinicaltrial.gov registrationNCT03056989. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 12, 2019 Category: Respiratory Medicine Source Type: research